AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03699956
Drug: Cisplatin/carboplatin plus etoposide
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care platinum doublet chemotherapy
Trial: NCT03733301
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally.
Trial: NCT03365869
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus or placebo were added to patients every day
Trial: NCT00483119
Drug: intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
Trial: NCT04668066
Drug: PF-07242813
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07242813 given intravenously or subcutaneous
Trial: NCT04254913
Drug: MT-1186
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension
Trial: NCT02685137
Drug: stannsoporfin
RxNorm normalized name: Stannsoporfin
DrugBank: Stannsoporfin (DB04912)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of stannsoporfin to treat jaundice.
Trial: NCT03156296
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
Trial: NCT03156296
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
Trial: NCT00707941
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows:~1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25
Trial: NCT02036853
Drug: Triheptanoin
RxNorm normalized name: Triheptanoin
DrugBank: Triheptanoin (DB11677)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Schedule A: Subjects previously treated with triheptanoin will continue to dose at approximately 35% of total daily calories (\~1-4g/kg/day, depending on age).~Schedule B: Subjects who are naïve to triheptanoin will begin a 2-week fixed titration schedule up until they have reached 35% of total daily calories (\~1-4 g/kg/day depending on age). If a subject has not reached the target of 35% of total daily calories, by the end of the 2-week fixed titration period, dose titration should continue until achieved or until the maximally tolerated dose has been established.
Trial: NCT03704285
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients undergoing general anesthesia using target controlled infusion of propofol. Initial bolus of 1-2 mg/kg and then a continuous infusion of 10 mg/kg/hr that will be adjusted adjusted to maintain a BIS between 40 and 60.
Trial: NCT01742286
Drug: Ceritinib
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via nasogastric/gastric (NG/G) tube. For patients in fasted group: 1-2 tablespoons (15-30 mL) of an appropriate food such as apple sauce or non-fat yogurt and a glass of water were allowed.~For patients in the fed cohort: LDK378 was taken with, or within 30 minutes after finishing a low-fat light snack containing 100-300 calories and 1.5-2 grams of fat.
Trial: NCT01134705
Drug: Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol
RxNorm normalized name: beclomethasone dipropionate Nasal Product
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
Trial: NCT03886311
Drug: Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks
Trial: NCT01573052
Drug: Chlordiazepoxide
RxNorm normalized name: Chlordiazepoxide
DrugBank: Chlordiazepoxide (DB00475)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg four times daily x 3 days then tapered over 3 days
Trial: NCT01573052
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg four times daily x 3 days then tapered over 3 days
Trial: NCT01779466
Drug: Desmopressin
RxNorm normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03944252
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
Trial: NCT03944252
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cetuximab 500 mg/m2 plus avelumab 10 mg/kg iv day 1. To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
Trial: NCT01215097
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: once a day
Trial: NCT00695097
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab infusion on Day 1 and Day 15
Trial: NCT00695097
Drug: No Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: No Rituximab
Trial: NCT02302339
Drug: glembatumumab vedotin
RxNorm normalized name: Glembatumumab vedotin
DrugBank: Glembatumumab vedotin (DB05996)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02302339
Drug: glembatumumab vedotin and varlilumab
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Glembatumumab vedotin (DB05996)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02302339
Drug: glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Glembatumumab vedotin (DB05996)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02302339
Drug: glembatumumab vedotin and CDX-301
RxNorm normalized name: CDX
DrugBank: Glembatumumab vedotin (DB05996)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02014337
Drug: Mifepristone and Eribulin in combination
RxNorm normalized name: mifepristone, combinations
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single Arm, Two Parts Part 1: Dose Escalation Phase to determine MTD and RP2D in up to 20 patients Part 2: Dose Expansion Phase at RP2D in 20 patients
Trial: NCT00899431
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months
Trial: NCT00899431
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m\^2 intravenously daily on days -5, -4, -3.
Trial: NCT00899431
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 intravenously on day -13, and 1000 mg/m\^2 on days -6, +1 and +8.
Trial: NCT00899431
Drug: Thymoglobulin
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg intravenously over 4 hours (day -2 and -1).
Trial: NCT00899431
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
Trial: NCT00899431
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
Trial: NCT03622476
Drug: concentrated FVIII
RxNorm normalized name: factor VIII
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention if the assessment considers that the treatment is inadequate
Trial: NCT01193504
Drug: Pred Forte
RxNorm normalized name: Pred Forte
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pred Forte BID for 4 weeks postop
Trial: NCT01193504
Drug: Lotemax
RxNorm normalized name: Lotemax
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lotemax BID for 4 weeks postop.
Trial: NCT03196362
Drug: Pioglitazone + Metformin
RxNorm normalized name: metformin / pioglitazone
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One tablet of fixed dose of Pioglitazone/ Metformin (15mg/30mg) will be given twice daily
Trial: NCT03756324
Drug: CHPM (Chinese Herbal Patent Medicine )
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pugongying (Herba Taraxaci) granules is named as Pugongying Granules in China and produced by Kunming pharmaceutical factory co. LTD. The form is granules, and the participants will take the medicine after dissolved as 15g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
Trial: NCT03756324
Drug: Antibiotics Cefdinir Capsules
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
Trial: NCT03756324
Drug: Antibiotics Cefdinir Capsules
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 2 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
Trial: NCT00077870
Drug: ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01448070
Drug: human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 0.2 IU/kg, administered subcutaneously (under the skin)
Trial: NCT00456859
Drug: Kremezin
RxNorm normalized name: METHYL SALICYLATE 31 g in 100 g / MENTHOL, UNSPECIFIED FORM 11 g in 100 g TOPICAL CREAM [FREEZIN COLD TOAST]
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00389168
Drug: Irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titrated to 300 mg od, 48 weeks.
Trial: NCT00389168
Drug: Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titrated to 100 mg od, 48 weeks.
Trial: NCT02203773
Drug: Posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole will be administered orally twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.
Trial: NCT02203773
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles
Trial: NCT02203773
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.
Trial: NCT00101374
Drug: Leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04237831
Drug: BMS-986259
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified Dose on Specified Days
Trial: NCT03832426
Drug: Narlaprevir
RxNorm normalized name: narlaprevir
DrugBank: Narlaprevir (DB14760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg film-coated tablets
Trial: NCT03832426
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg film-coated tablets
Trial: NCT02146534
Drug: extended release fampridine
RxNorm normalized name: dalfampridine Extended Release Oral Tablet
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pts will receive Fampyra 10 mg BID PO for the duration of the study
Trial: NCT03807921
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation
Trial: NCT03807921
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiplatelet treatment
Trial: NCT00267813
Drug: Bupropion (Zyban)
RxNorm normalized name: BUPROPION (ZYBAN) 150MG SA TAB PACK 60
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet a day increasing to 2 tablets a day after a week
Trial: NCT00077415
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00077415
Drug: triapine
RxNorm normalized name: Triapine
DrugBank: Triapine (DB11940)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02825875
Drug: 18F DCFPyL- Radiopharmaceutica
RxNorm normalized name: (18F)DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01525407
Drug: Atorvastatin Calcium
RxNorm normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02974738
Drug: Belzutifan
RxNorm normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis
Trial: NCT04535518
Drug: IVIG
RxNorm normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG at a single dose of 2 g/kg
Trial: NCT04535518
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
Trial: NCT04535518
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours.
Trial: NCT00566397
Drug: PF-04494700
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg for 6 days followed by daily dosing of 5mg
Trial: NCT04737304
Drug: BEN2293 (0.25% or 1.0% w/w) or matching placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.
Trial: NCT00566397
Drug: PF-04494700
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.
Trial: NCT02230319
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01345357
Drug: CEP-9722
RxNorm normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2. The starting dose will be 150 mg twice daily. Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients. Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily. Patients must receive CEP-9722 to remain in the study. Once treatment with CEP-9722 is discontinued, patients will withdraw from the study.
Trial: NCT01495793
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch:~Dose (size): 0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2) The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied.
Trial: NCT01345357
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be administered at 1250 mg/m\^2 intravenously on day 1 and day 8 of each 21-day cycle. Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
Trial: NCT01345357
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin will be administered at 75 mg/m\^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine. Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
Trial: NCT01942733
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment.
Trial: NCT01543633
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol will be infused using a computer controlled delivery system running the program STANPUMP. Loss of consciousness will be defined as loss of response to auditory stimulus (button press).
Trial: NCT02894541
Drug: CKD-519 100mg
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02894541
Drug: CKD-519 200mg
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00346970
Drug: Extended-Release Niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d
Trial: NCT03480243
Drug: Padsevonil (UCB0942)
RxNorm normalized name: Padsevonil
DrugBank: Padsevonil (DB14977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use
Trial: NCT05429749
Drug: Ferinject
RxNorm normalized name: epinephrine
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ferinject 1000mg is administered between the admission day and the surgery day.
Trial: NCT00610454
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00616785
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00616785
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00616785
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01195831
Drug: Calcipotriol scalp solution
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application
Trial: NCT00486291
Drug: VI-0521
RxNorm normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phentermine 15mg/topiramate 100mg
Trial: NCT04220476
Drug: Letrozole 2.5Mg Tab
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
Trial: NCT04220476
Drug: Palbociclib 125mg
RxNorm normalized name: PALBOCICLIB 125MG TAB
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.